Research & Clinical Partnerships
Accelerating access to evidence you can act on.
Reboot Rx works with clinicians, researchers, and health systems at the point where strong evidence exists for affordable cancer treatments, but no single organization is positioned to advance them. We contribute systematic evidence synthesis, independent prioritization, and pathway-focused analysis to help partners identify where generic drugs show real promise, and what would be required to evaluate them in clinical settings.
Our collaboration network includes organizations such as the Veterans Health Administration, National Cancer Institute, the SWOG Cancer Research Network, and leading cancer centers. These partnerships strengthen our ability to evaluate evidence rigorously, support real-world data analysis, and explore readiness for future clinical use.
In addition to research collaborators, Reboot Rx works with select pro bono partners who contribute legal, regulatory, and analytical expertise that supports evidence evaluation and pathway analysis.
Partners work with Reboot Rx because we bring:
Structured, cross-indication evidence synthesis that is difficult to replicate within a single institution
Independent, nonprofit prioritization grounded in clinical relevance, feasibility, and patient impact
Clear, decision-ready evidence materials that support research planning and clinical consideration
Analysis of regulatory, guideline, and health system pathways that shape how off-patent drugs can be studied and used
Why Partnership Makes a Difference
Promising repurposed drugs often stall after early research, not because of weak science but because no commercial institution is positioned to move them forward. By working together, partners can focus their expertise where it matters most, while Reboot Rx provides the connective tissue that links evidence, evaluation, and clinical decision-making.
Ways We Collaborate
Evidence Evaluation
Co-develop structured assessments of repurposing opportunities, accelerated by our AI-powered synthesis platform.
Clinical Studies
Partner on real-world data analyses, pragmatic studies, or randomized control trials to strengthen evidence where gaps remain.
Awareness-Building
Collaborate on efforts that inform when and how treatments could be considered in patient care.
Policy & Pathways
Work together to clarify regulatory, guideline, and payer pathways that shape how affordable, evidence-based treatments are evaluated and considered in clinical practice.